Krystal Biotech, Inc. KRYS
345.82
0.86
0.25%
as of 25 Sep
- Market cap
- $10.2B
- P/E
- 41.9×
Follow KRYS
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
19.66% | 18.91% | 19.90% | 20.12% | |
| 17.90% | 17.14% | 18.21% | 18.30% | ||
ROIC |
24.34% | 25.73% | 24.64% | 24.07% | |
Return on Tangible Assets |
20.23% | 19.10% | 21.12% | 22.23% | |
Average Days of Receivables |
126.80 | 119.52 | 111.10 | 114.90 | |
Free Cash Flow per Share |
5.73 | 6.54 | 8.11 | 8.73 | |
Free Cash Flow |
166.02 | 189.35 | 237.38 | 257.78 | |
Capital Expenditures |
(10.18) | (11.52) | (12.89) | (14.56) | |
Piotroski F-Score |
6.00 | 6.00 | 5.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
9.43% | 9.81% | 11.92% | 12.35% | |
Accounts Receivable Turnover |
3.29 | 3.35 | 3.62 | 3.52 | |
Accounts Payable Turnover |
5.58 | 5.61 | 7.20 | 3.46 | |
Inventory Turnover |
0.76 | 0.69 | 0.67 | 0.62 | |
Average Days of Payables |
35.76 | 51.28 | 61.31 | 101.14 | |
Days of Inventory on Hand |
641.70 | 640.96 | 639.41 | 704.10 | |
Tax Rate |
0.06 | 0.08 | 0.09 | 0.07 | |
Research and Development Expense of Revenue |
15.22% | 14.92% | 14.17% | 13.45% | |
Selling, General and Administrative Expense of Revenue |
36.60% | 37.71% | 37.17% | 36.30% | |
Share Based Compensation of Revenue |
14.50% | 14.01% | 13.09% | 12.41% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.89 | 0.98 | 1.11 | 1.13 | |
Depreciation/Fixed assets |
0.04 | 0.04 | 0.04 | 0.04 | |
Capex/Depreciation |
(1.60) | (1.76) | (1.94) | (2.18) | |
Revenue per Share |
12.89 | 13.44 | 14.25 | 14.92 | |
Operating CF per Share |
6.09 | 6.94 | 8.55 | 9.22 | |
Capex per Share |
(0.35) | (0.40) | (0.44) | (0.49) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.03 | |
Net Profit Margin |
53.30% | 52.64% | 53.92% | 54.82% |
Columns are period end dates